Karyopharm Therapeutics, Inc. (KPTI)
10.70
+0.67
(+6.68%)
USD |
NASDAQ |
Feb 24, 09:53
Karyopharm Therapeutics Research and Development Expense (Quarterly) : 27.65M for Dec. 31, 2025
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Alnylam Pharmaceuticals, Inc. | 372.22M |
| Baxter International, Inc. | 116.00M |
| Bruker Corp. | 99.60M |
| Catalyst Pharmaceuticals, Inc. | 2.657M |
| Agios Pharmaceuticals, Inc. | 86.79M |